Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS, then AHRQ’s, Tunis moves on

Executive Summary

Former Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis joins policy think tank Health Technology Center as a research fellow. Tunis most recently worked in the Agency for Healthcare Research & Quality's Office of Extramural Research, Education & Priority Populations (1"The Pink Sheet" Sept. 26, 2005, In Brief). Tunis left CMS in June after he accepted a fine and one-year suspension of his medical license to resolve charges that he falsified continuing medical education documents. Although HTC is based in San Francisco, Tunis will remain in Baltimore and hopes to resume practicing emergency medicine once his license is restored in 2006...

You may also be interested in...



CMS Needs Regulatory Science, Chief Scientist To Coordinate With US FDA, Former Official Says

Sean Tunis embraces a bigger decision-making role for CMS in product access, while FDA Commissioner nominee Robert Califf also calls for smoother FDA-CMS hand-offs, and CBER Director Peter Marks wants a quicker FDA-CDC approval and deployment process.

Tunis lands at AHRQ

Former CMS Chief Medical Officer Sean Tunis joins Agency for Healthcare Research & Quality's Office of Extramural Research, Education & Priority Populations Sept. 22 as a senior biomedical research scientist responsible for training health service researchers. In June, Tunis paid a $20,000 fine and accepted a one-year suspension of his physician's license to settle charges that he falsified his continuing medical education records (1"The Pink Sheet" June 13, 2005, p. 23). Tunis is ineligible to participate in federally funded health care programs due to his suspended license...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel